AV-412EGFR/ErbB2 kinase inhibitor CAS# 451493-31-5 |
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- Retaspimycin
Catalog No.:BCC1889
CAS No.:857402-23-4
- IPI-504 (Retaspimycin hydrochloride)
Catalog No.:BCC2126
CAS No.:857402-63-2
- PF-04929113 (SNX-5422)
Catalog No.:BCC2130
CAS No.:908115-27-5
- 17-AAG Hydrochloride
Catalog No.:BCC1297
CAS No.:911710-03-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 451493-31-5 | SDF | Download SDF |
| PubChem ID | 11700696 | Appearance | Powder |
| Formula | C41H44ClFN6O7S2 | M.Wt | 851.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | MP412 | ||
| Solubility | DMSO : ≥ 28 mg/mL (32.89 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide;4-methylbenzenesulfonic acid | ||
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C#CC1=CC2=C(C=C1NC(=O)C=C)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)N4CCN(CC4)C | ||
| Standard InChIKey | GTWJVFFZCKODEV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C27H28ClFN6O.2C7H8O3S/c1-5-25(36)33-23-16-20-24(30-17-31-26(20)32-19-6-7-22(29)21(28)15-19)14-18(23)8-9-27(2,3)35-12-10-34(4)11-13-35;2*1-6-2-4-7(5-3-6)11(8,9)10/h5-7,14-17H,1,10-13H2,2-4H3,(H,33,36)(H,30,31,32);2*2-5H,1H3,(H,8,9,10) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AV-412 (MP412) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.In Vitro:AV-412 inhibits autophosphorylation of EGFR and ErbB2 with IC50 of 43 and 282 nM, respectively. AV-412 also inhibits epidermal growth factor (EGF)-dependent cell proliferation with an IC50 of 100 nM. AV-412 abrogates EGFR signaling in the gefitinib-resistant H1975 cell line, which harbors a double mutation of L858R and T790M in EGFR[1].In Vivo:In animal studies using cancer xenograft models, AV-412 (30 mg/kg) demonstrates complete inhibition of tumor growth of the A431 and BT-474 cell lines, which overexpress EGFR and ErbB2, respectively. AV-412 suppresses autophosphorylation of EGFR and ErbB2 at the dose corresponding to its antitumor efficacy. When various dosing schedules are applied, AV-412 shows significant effects with daily and every-other-day schedules, but not with a once-weekly schedule, suggesting that frequent dosing is preferable for this compound. Furthermore, AV-412 shows a significant antitumor effect on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib[1]. References: | |||||
AV-412 Dilution Calculator
AV-412 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.1745 mL | 5.8726 mL | 11.7452 mL | 23.4904 mL | 29.3631 mL |
| 5 mM | 0.2349 mL | 1.1745 mL | 2.349 mL | 4.6981 mL | 5.8726 mL |
| 10 mM | 0.1175 mL | 0.5873 mL | 1.1745 mL | 2.349 mL | 2.9363 mL |
| 50 mM | 0.0235 mL | 0.1175 mL | 0.2349 mL | 0.4698 mL | 0.5873 mL |
| 100 mM | 0.0117 mL | 0.0587 mL | 0.1175 mL | 0.2349 mL | 0.2936 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AV-412 is a dual EGFR/ErbB2 kinase inhibitor with IC50 values of 43nM and 282nM, respectively [1].
In the H1650 and H1975 cell lines containing EGFR mutations, AV-412 inhibits EGFR autophosphorylation and the consequent activation of Akt and Erk at 0.1μM. In the H1781 cell line containing ErbB2 mutation, AV-412 also suppresses the phosphorylation of EGFR as well as ErbB2 and ErbB3. It decreases the phosphorylation of Akt and Erk [2].
AV-412 completely inhibits the tumor growth of both H1650 and H1975 xenografts in nude mice. It is proved that AV-412 suppresses tumor growth via the inhibition of EGFR. Besides that, AV-412 also shows antitumor effects against various tumor models expressing EGFR, ErbB2 or both receptors, such as breast cancer KPL-4, prostate cancer DU145 and lung cancer LC-376. The H520 lung cancer is not sensitive to AV-412 due to the lack of EGFR and ErbB2 in it [2].
References:
[1] Suzuki T, Fujii A, Ohya J, Amano Y, Kitano Y, Abe D, Nakamura H. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007 Dec;98(12):1977-84. Epub 2007 Sep 18.
[2] Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Cancer Sci. 2009 Aug;100(8):1526-31.
- AV-412 free base
Catalog No.:BCC5120
CAS No.:451492-95-8
- 10-Hydroxydihydroperaksine
Catalog No.:BCN5502
CAS No.:451478-47-0
- H-1152
Catalog No.:BCC1615
CAS No.:451462-58-1
- H-D-Glu(OtBu)-OH
Catalog No.:BCC2942
CAS No.:45125-00-6
- H-Glu-OtBu
Catalog No.:BCC2925
CAS No.:45120-30-7
- H-Aib-OtBu.HCl
Catalog No.:BCC3208
CAS No.:4512-32-7
- H-Met-NH2
Catalog No.:BCC2994
CAS No.:4510-08-1
- Homogentisic acid
Catalog No.:BCN3889
CAS No.:451-13-8
- FAK Inhibitor 14
Catalog No.:BCC7683
CAS No.:4506-66-5
- Specneuzhenide
Catalog No.:BCC9151
CAS No.:449733-84-0
- (+)-S-Myricanol glucoside
Catalog No.:BCN5501
CAS No.:449729-89-9
- VPC 23019
Catalog No.:BCC7883
CAS No.:449173-19-7
- Boc-N-Me-Val-OH
Catalog No.:BCC3357
CAS No.:45170-31-8
- SU14813 double bond Z
Catalog No.:BCC1972
CAS No.:452105-23-6
- GW788388
Catalog No.:BCC3666
CAS No.:452342-67-5
- Boc-DL-Phe-OH
Catalog No.:BCC3434
CAS No.:4530-18-1
- Boc-Gly-OH
Catalog No.:BCC3396
CAS No.:4530-20-5
- Saprirearine
Catalog No.:BCN3980
CAS No.:453518-30-4
- Motesanib
Catalog No.:BCC1776
CAS No.:453562-69-1
- PSB 11 hydrochloride
Catalog No.:BCC7239
CAS No.:453591-58-7
- Nudifloside D
Catalog No.:BCN7005
CAS No.:454212-54-5
- kobe2602
Catalog No.:BCC5291
CAS No.:454453-49-7
- Acetophenone tosylhydrazone
Catalog No.:BCC8804
CAS No.:4545-21-5
- Corosolic acid
Catalog No.:BCN5503
CAS No.:4547-24-4
Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.[Pubmed:19459856]
Cancer Sci. 2009 Aug;100(8):1526-31.
Although epidermal growth factor receptor (EGFR) kinase inhibitors are effective for the treatment of non-small cell lung cancer (NSCLC), the emergence of mutations resistant to these inhibitors, such as T790M, has become a clinical problem. Recently, ErbB2 mutations have also been identified in a small number of NSCLC patients. Therefore, novel therapies to overcome these mutations are desirable. We describe the antitumor activity of MP-412 (AV-412), a dual EGFR/ErbB2 kinase inhibitor, against three lung cancer models with EGFR and ErbB2 mutations and also against various human xenografts with overexpression of these receptors. MP-412 inhibited phosphorylation of EGFR and its downstream signaling in NCI-H1650 and NCI-H1975 cell lines, which harbor the E746-A750 deletion and L858R + T790M point mutations, respectively, in EGFR. MP-412 inhibited the growth of these cell lines in vitro and in vivo, whereas the precedent kinase inhibitors lapatinib, erlotinib, and gefitinib were ineffective against NCI-H1975 cells in vivo. Furthermore, MP-412 inhibited ErbB2 signaling in the NCI-H1781 cell line, which harbors the G776V,C insertion in ErbB2, and correlated with its antiproliferation activity. When its antitumor spectrum was further explored in several cancer types overexpressing EGFR or ErbB2, MP-412 showed potent activity in KPL-4 and DU145 xenografts, in which lapatinib was ineffective. MP-412 also inhibited tumor models in which conventional chemotherapies were less effective. These results suggest that MP-412 is a potent dual inhibitor with the potential for treating solid cancers that overexpress EGFR or ErbB2, including NSCLC cells harboring mutations resistant to the first generation of kinase inhibitors.
Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.[Pubmed:17888033]
Cancer Sci. 2007 Dec;98(12):1977-84.
Epidermal growth factor receptor (EGFR) and ErbB2 are currently recognized as validated target molecules in cancer treatment strategies. MP-412 (AV-412) is a potent dual inhibitor of EGFR and ErbB2 tyrosine kinases, including the mutant EGFR(L858R,T790M), which is clinically resistant to the EGFR-specific kinase inhibitors erlotinib and gefitinib. In an enzyme assay, MP-412 inhibited the EGFR variants and ErbB2 in the nanomolar range with over 100-fold selectivity compared with other kinases, apart from abl and flt-1, which were both moderately sensitive to the compound. In cells, MP-412 inhibited autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. It also inhibited epidermal growth factor (EGF)-dependent cell proliferation with an IC(50) of 100 nM. Moreover, MP-412 abrogated EGFR signaling in the gefitinib-resistant H1975 cell line, which harbors a double mutation of L858R and T790M in EGFR. In animal studies using cancer xenograft models, MP-412 (30 mg/kg) demonstrated complete inhibition of tumor growth of the A431 and BT-474 cell lines, which overexpress EGFR and ErbB2, respectively. MP-412 suppressed autophosphorylation of EGFR and ErbB2 at the dose corresponding to its antitumor efficacy. When various dosing schedules were applied, MP-412 showed significant effects with daily and every-other-day schedules, but not with a once-weekly schedule, suggesting that frequent dosing is preferable for this compound. Furthermore, MP-412 showed a significant antitumor effect on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib. These studies indicate that MP-412 has potential as a therapeutic agent for the treatment of cancers expressing EGFR and ErbB2, especially those resistant to the first generation of small-molecule inhibitors.
